Delivery Order SPE2DB22D3016-SPE2DB25FAYC7
- Not listed
- The Defense Logistics Agency awarded a $26,268.09 delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Tobi Podhaler 28 mg inhale capsules (56-unit doses). This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of September 10, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child delivery order, this award falls under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $28,423.85 delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Tobi Podhaler 28 mg inhalable capsules (56-count unit dose). This competitively awarded, firm fixed-price contract represents a non-set-aside procurement and is set for completion by September 9, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform delivery from its corporate office location in the same city. The...
- This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $34,972.30, is for the supply of the pharmaceutical product Tobi Podhaler 28 mg inhalation capsules. The contract is a Delivery Order with a Firm Fixed Price pricing type, and has an ultimate completion date of December 11, 2024. This award is part of a larger Indefinite Delivery Contract (IDC)...
- This is a delivery order contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $41,392.19, is for the delivery of Tobi Podhaler 28 mg inhalation capsules. The contract has a firm fixed price pricing type and an ultimate completion date of September 28, 2023. This award is not designated as a set-aside contract. Amerisourcebergen Drug Corp has an Indefinite Delivery Contract (IDC) with the...
- This federal contract award, valued at $18,676.17, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Tobi Podhaler 28 mg inhalation capsules and does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which has a significant Indefinite Delivery Contract (IDC) with the...
- This federal contract award, valued at $49,112.29, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office division. The delivery order contract is for the supply of 4,566,026,535 units of the pharmaceutical product TOBI PODHALER 28 MG INHALE CAP UD 56S. The contract has a firm fixed price pricing type and an ultimate completion date of October 7, 2024. Amerisourcebergen, a major pharmaceutical distributor, has been awarded numerous federal contracts to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Tobramycin 300 mg/4 mL ampules on May 20, 2025, with a ceiling value of $1,221.35 and an ultimate completion date of May 21, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing contract vehicle. The product will be delivered to the company's location in Conshohocken, Pennsylvania. This delivery order is issued...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order worth $28,502.07 to Amerisourcebergen Drug Corp, a subsidiary of parent company Cencora, Inc. The order is for the supply of 4,564,261,702 units of the medication Tobramycin 300 mg/4 ml ampules. The delivery order has an ultimate completion date of April 15, 2024. Amerisourcebergen Drug Corp, as a prime contractor, also holds an indefinite delivery contract (IDC) with DLA worth up to $999,999,999.00 through...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $35,434.99 firm fixed-price delivery order is for the supply of Tobramycin 300 mg/4 ml ampules, a critical antibiotic medication. The contract has an ultimate completion date of May 15, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on May 8, 2025, by the Defense Logistics Agency's Medical Supply Chain for the supply of Tobramycin 300 mg/5 mL ampule unit dose 5 mL under a firm fixed-price contract. The contract carries a ceiling value of $3,713.43 with an ultimate completion date of May 9, 2025, and was competitively awarded with no set-aside designation. This delivery order represents...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FAYC7Delivery Order
The Defense Logistics Agency awarded a $33,712.95 delivery order to AmerisourceBergen Drug Corp for Tobi Podhaler 28 mg inhalable capsules (56-unit dose packages) on June 2, 2025, with completion scheduled for June 3, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order supports the Defense Logistics Agency's Medical Supply Chain operations, which procure critical pharmaceuticals and medical supplies for military and veteran healthcare systems. AmerisourceBergen Drug Corp's comprehensive IDC vehicle enables the company to supply a wide range of pharmaceutical products across multiple therapeutic domains to customers including the Defense Health Agency and U.S. Coast Guard. The Tobi Podhaler product is a specialized respiratory medication used in cystic fibrosis treatment, reflecting the company's role as a key vendor for specialized medical commodities supporting federal healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $33.7k | 6/2/25 |